CONMED (CNMD) 44th Annual J.P. Morgan Healthcare Conference summary

Strategic vision and portfolio focus

• Emphasizes empowering healthcare providers globally with innovative clinical solutions and maintaining a balanced portfolio between general surgery (58%) and orthopedics (42%).

• Prioritizes high-growth, high-margin platforms: AirSeal, Buffalo Filter, and BioBrace, while exiting the GI/gastroenterology business to focus on minimally invasive surgery and orthopedic soft tissue repair.

• Geographic revenue split is 57% U.S. and 43% international, with 86% of sales from single-use products supporting durable growth.

• Portfolio optimization is ongoing, prioritizing segment leadership and high-return categories in minimally invasive surgery and sports medicine.

• Portfolio review is now a continuous process, with future growth expected from additions rather than subtractions.

Growth drivers and market opportunities

• AirSeal portfolio targets both robotic and laparoscopic markets, with 60% of sales from robotics and 40% from laparoscopy; laparoscopy is growing faster.

• Buffalo Filter smoke evacuation benefits from global legislation and clinical validation, with the market expected to grow from $300–$350 million to $1 billion.

• BioBrace is the only FDA-cleared implant for both mechanical reinforcement and bioinductivity in soft tissue repair, with strong clinical outcomes and expanding indications.

• High-growth categories include foot & ankle, AirSeal, smoke evacuation, and sports medicine, with expected mid-term revenue growth of 4% to 11% across segments.

• Direct smoke evacuation and AirSeal are prioritized over OEM business, which is expected to decline.

Financial performance and guidance

• 2026 revenue guidance ranges from $1.345–$1.450 billion, with adjusted EPS of $4.25–$4.45 after GI exit, tariffs, and FX impacts.

• Organic constant currency revenue growth is guided at 4–6% for 2026.

• Share repurchase replaces dividend, with at least $25 million allocated in 2026 and a $150 million buyback program announced.

• Leverage reduced below 3x ahead of schedule; focus remains on maintaining financial strength and durable cash flow, with free cash flow conversion exceeding 100% in recent years.

• Revenue has grown from $955 million in 2019 to $1,372 million in 2024, with 2025 guidance up to $1,365 million.